Replimune stock (ticker: REPL) cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year.

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.  Researchers from the University of California San Francisco developed and ...

Replimune (REPL) stock slides after as FDA rejects its melanoma drug RP1, boosting shares of Iovance Biotherapeutics (IOVA) which markets a rival drug. Read more here.